The topoisomerase I inhibitor DX-8951f is active in a severe combined immunodeficient mouse model of human acute myelogenous leukemia

Clinical Cancer Research

Volumn 6, Issue 2, 2000, Pages 731-736

  Vey, Norbert ^a   Giles, Francis J ^a   Kantarjian, Hagop ^a   Smith, Terry L ^a   Beran, Miloslav ^a   Jeha, Sima ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE INHIBITOR; EXATECAN;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DEATH; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCID MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DNA TOPOISOMERASES, TYPE I; FEMALE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MICE; MICE, SCID; SURVIVAL ANALYSIS; TIME FACTORS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0033976287     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Kantarjian, H. M., Beran, M, Ellis, A., Zwelling, L., O'Brien, S., Cazenave, L., Koller, C., Rios, M. B., Plunkett, W., and Keating, M. J. Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood, 81: 1146-1151, 1993.
2. Beran, M., Estey, E., O'Brien, S. M., Giles, F. J., Koller, C. A., Kornblau, S., Keating, M., and Kantarjian, H. M. Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk. Lymphoma, 31: 521-531, 1998.
3. Beran, M., Kantarjian, H., O'Brien, S., Koller, C., al-Bitar, M., Arbuck, S., Pierce, S., Moore, M., Abbruzzese, J. L., Andreeff, M., Keating, M., and Estey, E. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood, 88: 2473-2479, 1996.
4. Mitsui, I., Kumazawa, E., Hirota, Y., Aonuma, M., Sugimori, M., Ohsuki, S., Uoto, K., Ejima, A., Terasawa, H., and Sato, K. A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo. Jpn. J. Cancer Res., 86: 776-782, 1995.
5. Takiguchi, S., Kumazawa, E., Shimazoe, T., Tohgo, A., and Kono, A. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice. Jpn. J. Cancer Res., 88: 760-769, 1997.
6. Joto, N., Ishii, M., Minami, M., Kuga, H., Mitsui, I., and Tohgo, A. DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant. Int. J. Cancer. 72: 680-686, 1997.
7. Takimoto, C. H., Wright, J., and Arbuck, S. G. Clinical applications of the camptothecins. Biochim. Biophys. Acta, 1400: 107-119, 1998.
8. Kumazawa, E., Jimbo, T., Och, Y., and Tohgo, A. Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice. Cancer Chemother. Pharmacol., 42: 210-220, 1998.
9. Beran, M., Pisa, P., Kantarjian, H., Porwit, A., and Bjorkholm, M. Growth of sensitive and drug-resistant human myeloid leukemia cells in SCID mice. Hematol. Pathol., 8: 135-154, 1994.
10. Beran, M., Jeha, S., O'Brien, S., Estey, E., Vitek, L., Zurlo, M. G., Rios, M. B., Keating, M., and Kantarjian, H. Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a Phase I study. Clin. Cancer Res., 3: 2377-2384, 1997.
11. Jeha, S., Kantarjian, H., O'Brien, S., Vitek, L., and Beran, M. Activity of oral and intravenous 9-aminocamptothecin in SCID mice engrafted with human leukemia. Leuk. Lymphoma, 32: 159-164, 1998.
12. Vey, N., Kantarjian, H., Tran, H., Beran, M., O'Brien, S., Bivins, C., Giles, C., Cortes, J., Arbuck, S., and Estey, E. Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia. Ann. Oncol., 10: 577-583, 1999.
13. Andersson, B. S., Bergerheim, U. S., Collins, V. P., Childs, C., Beran, M., Sen, S., Arden, K., Pathak, S., Siciliano, M. J., and Ost, A. KBM-3, an in vitro model of human acute myelomonocytic leukemia. Exp. Hematol., 20: 361-367, 1992.
14. Beran, M., Pisa, P., O'Brien, S., Kurzrock, R., Siciliano, M., Cork, A., Anderson, B. S., Kohli, V., and Kantarjian, H. Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase. Cancer Res., 53: 3603-3610, 1993.
15. Meyuhas, O., and Klein, A. The mouse ribosomal protein L7 gene. J. Biol. Biochem., 265; 11465-11473, 1990.
16. Kaplan, E., and Meier P. Nonparametric estimation for incomplete estimation. J. Am. Stat. Assoc., 53: 457-462, 1958.
17. Vey, N., Keating, M., Giles, F., Cortes, J., Beran, M., and Estey, E. Effect of complete remission on survival in patients with acute myelogenous leukemia receiving first salvage therapy. Blood, 93: 3149-3150, 1999.
18. Arbuck, S. G., and Takimoto, C. H. An overview of topoisomerase I-targeting agents. Semin. Hematol., 35: 3-12, 1998.
19. Supko, J., Plowman, D., and Dykes, J. Relationship between the schedule dependence of 9-amino-20-(S)-camptothecin (AC, NSC 603071) antitumor activity in mice and its plasma pharmacokinetics. Proc. Am. Assoc. Cancer Res., 33: 432, 1992.